MedTech World Magazine: The future of stem cell therapy

Stem cell therapy is opening new possibilities in regenerative medicine, particularly for complex conditions with limited treatment options. Duncan Barry interviews Yan Meng, Executive Director, CSU Xiangya Pharmaceutical Cell Medical Technology (Shenzhen) Co., Ltd, on its pioneering new approaches in regenerative medicine.

CSU Xiangya Pharmaceutical Cell Medical Technology is pioneering new approaches in regenerative medicine. Can you tell us about the company’s mission and what sets it apart in the field of stem cell technology?

CSU Xiangya Pharmaceutical Cell Medical Technology was jointly established by Xiangya Pharmaceutical and FANCELL Innovative Pharmaceutical. Our core innovation is a proprietary neural-targeted stem cell and extracellular vesicle (EV) platform, which we are applying to the treatment of neurological disorders such as autism spectrum disorder and Alzheimer’s disease. Our mission is to harness advanced cell technologies to help restore cognitive function and improve patients’ quality of life, with the hope of reducing the emotional and social burden these conditions place on families.

Your work focuses on innovative neural and targeted stem cell therapies. What are the biggest breakthroughs you’ve achieved so far?

Our neural-targeted stem cell and extracellular vesicle technology has entered clinical research at several leading tertiary hospitals in China. To date, close to one hundred children with autism spectrum disorder and elderly patients with Alzheimer’s disease have participated in these studies, with many showing improvements in their overall health status and daily functioning, enabling them to better reintegrate into family life.

The company is developing therapies for conditions ranging from autism spectrum disorder and Alzheimer’s disease to stroke, Parkinson’s disease and heart disease. What makes stem cell technology such a promising approach for these complex disorders?

Stem cells possess unique biological properties, including tissue repair, cellular differentiation and immune modulation. They have the potential to differentiate into functional nerve cells that may replace damaged neurons, while also secreting a range of neurotrophic factors that help improve the brain’s microenvironment. This multifaceted therapeutic approach offers possibilities beyond symptom management and may address underlying disease mechanisms that conventional therapies have struggled to target.

Neurological diseases have traditionally been among the most difficult to treat. How is your research changing what’s possible for patients?

We have developed genetically modified neural stem cells delivered via extracellular vesicles, using specific protein-mediated mechanisms to regulate the gut-brain axis. Combined with an innovative non-invasive delivery system using nebulisation and intranasal administration, our platform leverages the natural signalling capabilities of extracellular vesicles to cross the blood-brain barrier efficiently and deliver targeted therapeutic components directly to sites of neurological injury.

Your technologies have received international patents and are already being applied clinically. How important is it to bridge the gap between laboratory research and real-world patient care?

Bridging the gap between laboratory innovation and real patient needs is essential. It is the only meaningful pathway for translating patented technologies and promising preclinical research into clinically validated therapies. This translational approach has been a key driver of our work in autism spectrum disorder, Alzheimer’s disease and other neurological conditions, where we aim to deliver measurable improvements in patient outcomes.

Collaboration appears to be central to your work. How have partnerships with institutions such as the Vanderbilt Cell Research Institute, Sun Yat-sen University and other research organisations accelerated innovation?

These research partnerships provide the scientific foundation that underpins our technology platform. Together, we collaborate on technology development, process optimisation, clinical evaluation frameworks, and rigorous assessments of safety and efficacy. By combining expertise across multiple disciplines, we have been able to accelerate innovation and achieve significant advances in both research and clinical translation.

The company is also developing extracellular vesicle technology and advanced drug delivery systems. Could you explain what these are and why they represent an exciting area of research?

Extracellular vesicles are naturally secreted nanoscale membrane-bound particles that serve as biological carriers for intercellular communication. In our platform, they can transport key functional components derived from genetically engineered neural stem cells while also helping regulate the gut-brain axis. Coupled with our innovative nebulised and intranasal, non-invasive delivery system, extracellular vesicles can facilitate the targeted transport of therapeutic payloads across the blood-brain barrier to affected neurological tissues – addressing one of the major challenges in treating diseases of the central nervous system.

Finally, what is your long-term vision for CSU Xiangya Pharmaceutical Cell Medical Technology, and what impact do you hope the company will have on the future of global healthcare?

Drawing on the integrated strengths of Xiangya’s research, clinical and industrial resources, our long-term goal is to develop effective therapies for complex diseases that remain difficult to treat, including neurodegenerative disorders and chronic non-healing wounds. We are committed to advancing cell biotechnology from the laboratory into accessible clinical practice and to helping establish internationally recognised standards for cell-based therapies developed in China. Ultimately, we hope our innovations will contribute to improving healthcare outcomes for patients around the world.

If you have a story to tell or an insight to share, we’d love to hear from you for a future edition of the magazine.

Up next: MedTech World Europe 2026 | Malta

MedTech World returns to Malta for MedTech World Europe 2026, its biggest edition yet. Taking place from 11-13 November 2026, MedTech Malta Week expands the traditional conference into a five-day experience across Malta and Gozo, bringing together investors, founders, healthcare leaders, innovators, and industry experts from across the global MedTech ecosystem.

The week opens with the MedTech World Investors Retreat in Gozo from 9–11 November, offering accredited investors and senior industry leaders an exclusive setting for strategic conversations, networking, workshops, and curated experiences. The programme then moves to Malta for a cultural immersion day in Valletta and Mdina on 11 November, before the main MedTech World Europe conference takes place from 11 to 13 November at the Mediterranean Conference Centre in Valletta.

Throughout the conference, attendees can expect keynote sessions, panel discussions, workshops, company showcases, investor meetings, an exhibition floor, and the MedTech World Startup Pitch Competition, followed by the MedTech World Gala Awards, honoring achievements across the global MedTech ecosystem.

Interested in being part of the biggest MedTech World Europe yet? Book your ticket now.